Youthful systemic factors restore aged liver regeneration through LTβ-driven hepatocyte reprogramming

Study limitation reported by the research below: “LTBR agonist antibody use is preclinical only; immune-related risks of systemic LTBR activation (e.g., lymphoid tissue remodeling, inflammatory effects) have not been assessed in humans.”